Search

Your search keyword '"Müller, Michael J."' showing total 28 results
Start Over Author "Müller, Michael J."
28 results on '"Müller, Michael J."'

4. ADVANCING SCIENCE AND SERVICES DURING THE 2015/16 EL NIÑO : The NOAA El Niño Rapid Response Field Campaign

Author

Dole, Randall M., Spackman, J. Ryan, Newman, Matthew, Compo, Gilbert P., Smith, Catherine A., Hartten, Leslie M., Barsugli, Joseph J., Webb, Robert S., Hoerling, Martin P., Cifelli, Robert, Wolter, Klaus, Barnet, Christopher D., Gehne, Maria, Gelaro, Ronald, Kiladis, George N., Abbott, Scott, Akish, Elena, Albers, John, Brown, John M., Cox, Christopher J., Darby, Lisa, de Boer, Gijs, DeLuisi, Barbara, Dias, Juliana, Dunion, Jason, Eischeid, Jon, Fairall, Christopher, Gambacorta, Antonia, Gorton, Brian K., Hoell, Andrew, Intrieri, Janet, Jackson, Darren, Johnston, Paul E., Lataitis, Richard, Mahoney, Kelly M., McCaffrey, Katherine, McColl, H. Alex, Mueller, Michael J., Murray, Donald, Neiman, Paul J., Otto, William, Persson, Ola, Quan, Xiao-Wei, Rangwala, Imtiaz, Ray, Andrea J., Reynolds, David, Dellaripa, Emily Riley, Rosenlof, Karen, Sakaeda, Naoko, Sardeshmukh, Prashant D., Slivinski, Laura C., Smith, Lesley, Solomon, Amy, Swales, Dustin, Tulich, Stefan, White, Allen, Wick, Gary, Winterkorn, Matthew G., Wolfe, Daniel E., and Zamora, Robert

Published
2018

13. LETTERS

Author

Bounds, Sammy J., Murray, Michael Patrick, Johnson, Gary T., Wefso, James R., Millstein, David J., Barr, Nichole M., Fahrenkrug, Mark R., Wellington, Ralph G., Winkelman, Nancy, Refsin, Barry L., Mueller, Michael J., and Patton, Thomas E.

Published
1995

17. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

Author

Grishina, Olga, primary, Schmoor, Claudia, additional, Döhner, Konstanze, additional, Hackanson, Björn, additional, Lubrich, Beate, additional, May, Annette M., additional, Cieslik, Caroline, additional, Müller, Michael J., additional, and Lübbert, Michael, additional

Published
2015
Full Text
View/download PDF

27. Formal specification of beliefs in multi-agent systems

Author

Luciano Serafini, Fausto Giunchiglia, Massimo Benerecetti, Alessandro Cimatti, Enrico Giunchiglia, Jörg P. Müller, Michael J. Wooldridge, Nicholas R. Jennings, Benerecetti, Massimo, Alessandro, Cimatti, Enrico, Giunchiglia, Fausto, Giunchiglia, and Luciano, Serafini

Subjects
Language Of Temporal Ordering Specification, Management science, Computer science, Formal specification, System requirements specification, Specification language, Refinement, Formal methods, Grammar systems theory, Formal verification
Abstract

The formalization of agents attitudes, and belief in particular, has been investigated in the past by the authors of this paper, along two different but related streams. Giunchiglia and Giunchiglia investigate the properties of contexts for the formal specification of agents mutual beliefs, combining extensional specification with (finite) presentation by means of contexts. Cimatti and Serafini address the representational and implementational implications of the use of contexts for representing prepositional attitudes by tackling a paradigmatic case study. The goal of this paper is to show how these two streams are actually complementary, i.e. how the methodology proposed in the former can be successfully applied to formally specify the case study discussed in the latter. In order to achieve this goal, the formal framework is extended to take into account some relevant aspects of the case study, the specification of which is then worked out in detail.

Published
1997

28. Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.

Author

Harder J, Müller MJ, Fuchs M, Gumpp V, Schmitt-Graeff A, Fischer R, Frank M, Opitz O, and Hasskarl J

Subjects
Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms pathology, Bile Duct Neoplasms therapy, Bile Ducts, Extrahepatic pathology, Bile Ducts, Intrahepatic pathology, Cholangiocarcinoma pathology, Cholangiocarcinoma therapy, Female, Gallbladder Neoplasms pathology, Gallbladder Neoplasms therapy, Humans, Immunohistochemistry, Inhibitor of Differentiation Protein 1 analysis, Inhibitor of Differentiation Protein 2 analysis, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Proteins analysis, Neoplasm Staging, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Bile Duct Neoplasms chemistry, Bile Ducts, Extrahepatic chemistry, Bile Ducts, Intrahepatic chemistry, Cholangiocarcinoma chemistry, Gallbladder Neoplasms chemistry, Inhibitor of Differentiation Proteins analysis
Abstract

Aim: To investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer., Methods: ID protein expression was analyzed in 129 samples from patients with advanced biliary tract cancer (BTC) (45 extrahepatic, 50 intrahepatic, and 34 gallbladder cancers), compared to normal controls and correlated with clinical an pathological parameters., Results: ID1-3 proteins are frequently overexpressed in all BTC subtypes analyzed. No correlation between increased ID protein expression and tumor grading, tumor subtype or treatment response was detected. Survival was influenced primary tumor localization (extrahepatic vs intrahepatic and gall bladder cancer, OS 1.5 years vs 0.9 years vs 0.7 years, P = 0.002), by stage at diagnosis (OS 2.7 years in stage I vs 0.6 years in stage IV, P < 0.001), resection status and response to systemic chemotherapy. In a multivariate model, ID protein expression did not correlate with clinical prognosis. Nevertheless, there was a trend of shorter OS in patients with loss of cytoplasmic ID4 protein expression (P = 0.076)., Conclusion: ID protein expression is frequently deregulated in BTC but does not influence clinical prognosis. Their usefulness as prognostic biomarkers in BTC is very limited.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results